# A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

Study · id `cardio:ct-nct02059616` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02059616](<https://clinicaltrials.gov/study/NCT02059616>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02059616

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 384 participants.

## Technical summary

Registry record NCT02059616. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 384 participants (planned count; ClinicalTrials.gov record NCT02059616, source copy `cardio:ctgov-nct02059616-2014-04-30`, retrieved 2026-10-26)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT02059616, source copy `cardio:ctgov-nct02059616-2014-04-30`, retrieved 2026-10-26)
- Primary completion: 2015-06 (anticipated) (ClinicalTrials.gov record NCT02059616, source copy `cardio:ctgov-nct02059616-2014-04-30`, retrieved 2026-10-26)
- Completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT02059616, source copy `cardio:ctgov-nct02059616-2014-04-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02059616, source copy `cardio:ctgov-nct02059616-2014-04-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02059616-2014-04-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Amlodipine 5mg
- Intervention (Drug): Amlodipine 10mg
- Intervention (Drug): Candesartan Cilexetil 8mg
- Intervention (Drug): Candesartan cilexetil 16mg
- Lead sponsor: HK inno.N Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: HK inno.N Corporation (`cardio:org-hk-inno-n-corporation`)

## Provenance

Content hash: 27bfaad723c8a135c75bfa648eda1099e52396f2c90a0adda05e38d13686d7a7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
